SCHEMBL6281222

SCHEMBL6281222

CC(c1ccncc1)S(N)(=O)=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.40
CYP2C19 P33261 1/20 0.40
MAPT P10636 1/20 0.38
GAA P10253 1/20 0.37
SLC6A2 P23975 1/20 0.37
SLC6A4 P31645 1/20 0.37
SLC6A3 Q01959 1/20 0.37
HPGD P15428 1/20 0.36
ALDH1A1 P00352 2/20 0.36
POLB P06746 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CA12 O43570 4/20 0.35
CA1 P00915 4/20 0.35
CA2 P00918 4/20 0.35
CA9 Q16790 4/20 0.35
CA14 Q9ULX7 3/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
CYP19A1 P11511 2/20 0.34
ROCK2 O75116 2/20 0.34
ROCK1 Q13464 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27451597 0.82 CYP3A4 (0.43) CYP3A4CYP2C19MAPTGAASLC6A2
SCHEMBL28960603 0.79 GAA (0.39) CYP3A4CYP2C19GAASLC6A2SLC6A4
SCHEMBL7343137 0.78 CYP3A4 (0.40) CYP3A4CYP2C19MAPTGAASLC6A2
SCHEMBL1645022 0.78 HPGD (0.43) CYP3A4CYP2C19MAPTGAASLC6A2
SCHEMBL18028786 0.77 PTGES2 (0.44) MAPTHPGDALDH1A1POLBCA12
SCHEMBL1792962 0.77 PTGES2 (0.44) MAPTHPGDALDH1A1POLBCA12
SCHEMBL18028833 0.77 PTGES2 (0.44) MAPTHPGDALDH1A1POLBCA12
SCHEMBL11554283 0.77 HPGD (0.42) CYP3A4CYP2C19MAPTGAASLC6A2
Potassium Ion SCHEMBL8396295 0.77 CYP3A4 (0.39) CYP3A4CYP2C19MAPTGAASLC6A2
Hydrochloric Acid SCHEMBL4971841 0.77 CYP3A4 (0.39) CYP3A4CYP2C19MAPTGAASLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6887903-B1 N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them DOMPE S.P.A. (IT) 2005-05-03 US disclosed
US-6881755-B2 N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them Dompé S.p.A. (IT) 2005-04-19 US disclosed
US-20030216392-A1 N - ( 2 - aryl - propionyl ) - sulfonamides and pharmaceutical preparations containing them DOMPE S.P.A. 2003-11-20 US disclosed
EP-1123276-B1 N-(2-ARYL-PROPIONYL)-SULFONAMIDES AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM DOMPE SPA (IT) 2003-01-08 EP disclosed
EP-1123276-A1 N-(2-ARYL-PROPIONYL)-SULFONAMIDES AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM Dompe' S.P.A. (IT) 2001-08-16 EP disclosed
WO-2000024710-A1 N-(2-ARYL-PROPIONYL)-SULFONAMIDES AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM DOMPE' S.P.A. (IT) 2000-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030216392-A1 N - ( 2 - aryl - propionyl ) - sulfonamides and pharmaceutical preparations containing them ELANE, MPO, FPR1 CYP3A4 1110/4885CYP2C19 1029/4885MAPT 4727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.